Affibody Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$21M
- Investors
-
4
Affibody General Information
Description
Developer of radioligand therapies designed to selectively target tumors across a broad range of cancers. The company offers Affibody molecule-based radioligand therapies and a drug discovery platform for oncology, immunology, and inflammation, enabling healthcare providers and biopharmaceutical partners to develop targeted treatments for patients with high unmet medical needs.
Contact Information
Website
www.affibody.seCorporate Office
- Scheeles väg 2
- 171 65 Solna
- Sweden
Corporate Office
- Scheeles väg 2
- 171 65 Solna
- Sweden
Affibody Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Debt - General | 22-Dec-2022 | $21M | Completed | Profitable | ||
| 6. Secondary Transaction - Private | 01-Feb-2021 | Completed | Profitable | |||
| 5. Later Stage VC | 08-Mar-2018 | Completed | Profitable | |||
| 4. Secondary Transaction - Private | 01-Jan-2014 | Completed | Profitable | |||
| 3. Later Stage VC | 30-Mar-2007 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 03-Oct-2001 | $28M | $28M | Completed | Startup | |
| 1. Early Stage VC | 30-Jun-2000 | Completed | Startup |
Affibody Patents
Affibody Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026114946-A1 | Izokibep for use in a treatment of psoriatic arthritis | Pending | 26-Nov-2024 | ||
| AU-2025212066-A1 | Her2-binding polypeptide | Pending | 25-Jan-2024 | ||
| WO-2025158010-A1 | Her2-binding polypeptide | Pending | 25-Jan-2024 | ||
| EP-4773985-A1 | Methods of treating hidradenitis suppurativa | Pending | 08-Sep-2023 | ||
| WO-2025054498-A1 | Methods of treating hidradenitis suppurativa | Inactive | 08-Sep-2023 | A61P17/00 |
Affibody Signals
Affibody Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Investor | PE/Buyout | Minority | ||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| KTH Ventures | Venture Capital | Minority |
Affibody Acquisitions (1)
Affibody’s most recent deal was a Merger/Acquisition with Visual Bioinformatics. The deal was made on 29-Jun-2001.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Visual Bioinformatics | 29-Jun-2001 | Merger/Acquisition | Other Healthcare Technology Systems |
Affibody FAQs
-
When was Affibody founded?
Affibody was founded in 1998.
-
Where is Affibody headquartered?
Affibody is headquartered in Solna, Sweden.
-
What is the size of Affibody?
Affibody has 65 total employees.
-
What industry is Affibody in?
Affibody’s primary industry is Drug Discovery.
-
Is Affibody a private or public company?
Affibody is a Private company.
-
What is Affibody’s current revenue?
The current revenue for Affibody is .
-
How much funding has Affibody raised over time?
Affibody has raised $102M.
-
Who are Affibody’s investors?
Investor, , , and KTH Ventures have invested in Affibody.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process